Pharmaceutical Intermediates

This product is pharmaceutical raw materials and pharmaceutical intermediates.

(2R,4S)-5-([1,1'-Biphenyl]-4-Yl)-4-((Tert-Butoxycarbonyl)Amino)-2-Methylpentanoic Acid is a key intermediate in the preparation of sacubitril.

Lipoic acid is an endogenous antioxidant, which can remove the body's free radicals, promote the body's synthesis of vitamin C using glucose, and promote the synthesis of glutathione, effectively remove melanin, and assist coenzyme in physiological metabolism conducive to the body's immunity. Lipoic acid also has anti-inflammatory effect, can inhibit the activities of kinase, transforming factor, tumor necrosis factor and collagenase, and has anti-aging effect. Lipoic acid can preserve and regenerate other antioxidants and has a good health function to human body. It is widely used in the prevention and treatment of heart disease, diabetes, liver disease and Alzheimer's disease. The two enantiomers of lipoic acid showed different biological activities. Among them, R-type enantiomers are more effective than S-type enantiomers, which may be due to the fact that a large amount of R-type lipoic acid can enter cells and mitochondria through cell membrane and mitochondrial membrane and be reduced to dihydrolipoic acid, while only a small amount of S-type can enter cells and be reduced. Dihydrolipoic acid has stronger antioxidant capacity than lipoic acid. The regeneration of endogenous antioxidants and the repair of oxidative damage can only be achieved by dihydrolipoic acid.

LCZ696 intermediate is an intermediate of organic synthesis and pharmaceutical research and development. It is mainly used as an organic intermediate and pharmaceutical intermediate. It can be used in laboratory research and development process and chemical pharmaceutical synthesis process. It can be used in the synthesis of API entresto. Entresto is a salt complex crystal composed of sacubatre and Valsartan in a molar ratio of 1:1. It is the first angiotensin receptor enkephalinase inhibitor (Arni) to reduce the risk of cardiovascular death and hospitalization for heart failure.

4,6-dichloro-2 - (propylthio) - 5-aminopyrimidine is a pharmaceutical intermediate, which can be used as the intermediate of anticoagulant drug ticagrel.